A push for change: a review of the sue of advanced neuroimaging in the urgent evaluation of acute stroke, and the impact on clinical guidelines
In 1996, the United States Food and Drug Administration officially approved the use of intravenous recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke, with the requirement that a baseline computed tomography (CT) scan be performed to rule out acute intracerebral or...
| Main Author: | |
|---|---|
| Language: | en_US |
| Published: |
2016
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/15054 |